Dr. Lorenza Rimassa on Tivantinib for EGFR Inhibitor-Resistant mCRC

Lorenza Rimassa, MD
Published: Saturday, Jul 04, 2015



Lorenza Rimassa, MD, Deputy Director - Medical Oncology Unit - Humanitas Cancer Center, Humanitas Research Hospital, discusses a study looking at tivantinib (ARQ 197), a highly selective MET inhibitor, for the treatment of Metastatic Colorectal Cancer (mCRC).

The study looked at tivantinib in Combination with cetuximab in EGFR inhibitor-resistant, MET-High, KRAS Wild-Type (KRASwt) mCRC.

In the first stage of the study, three out of the 21 patients enrolled had an objective response and eight had stable disease. These results are exciting because all of the patients enrolled in the study had already become resistant to all of the treatment available, said Rimassa.

A phase II study with 41 patients has just completed enrollment. Results are expected at the end of the year.



Lorenza Rimassa, MD, Deputy Director - Medical Oncology Unit - Humanitas Cancer Center, Humanitas Research Hospital, discusses a study looking at tivantinib (ARQ 197), a highly selective MET inhibitor, for the treatment of Metastatic Colorectal Cancer (mCRC).

The study looked at tivantinib in Combination with cetuximab in EGFR inhibitor-resistant, MET-High, KRAS Wild-Type (KRASwt) mCRC.

In the first stage of the study, three out of the 21 patients enrolled had an objective response and eight had stable disease. These results are exciting because all of the patients enrolled in the study had already become resistant to all of the treatment available, said Rimassa.

A phase II study with 41 patients has just completed enrollment. Results are expected at the end of the year.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x